Clinical Trial

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
Protocol Amendment History 5 changes
critical Trial completed 2026-08-05
notable Enrollment reduced: 32 -> 16 participants 2026-08-05
notable Primary completion moved earlier: 2026-08 -> 2026-06-05 2026-08-05
minor Completion moved earlier: 2026-08 -> 2026-06-05 2026-08-05
critical Recruitment opened 2026-04-01
Trial Details
NCT Number NCT07425899
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 16 participants
Start Date 2026-02-26
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-04